
AI Video Summaries & Media Intelligence from YouTube Creators
🔥 Most Discussed Stocks in Videos (Last 30 Days)
No top picks available in the last 30 days.
Filter by Channel
No Financial or Investment Advice: TubeFolio is an AI-powered media productivity software that transcribes, summarizes, and aggregates publicly available YouTube content. All insights, topic frequencies, and creator mentions are provided strictly for general informational, educational, and media research purposes under the publisher's exemption of the US Investment Advisers Act of 1940 (*Lowe v. SEC*, 472 U.S. 181 (1985)) and EU MAR No. 596/2014.
Risk Warning: Summaries reflect third-party creator opinions on YouTube. TubeFolio does not provide personalized investment advice or buy/sell recommendations. Users act entirely at their own risk.
Viewing time-delayed data

Palantir Just Did The Unthinkable
Tom Nash
Tom argues that the recent 53% drop in Palantir (PLTR) is an overreaction to a false narrative about Anthropic. He states that PLTR's robust fundamentals, including significant revenue and operating income growth, indicate it's a "massive bargain" and an opportunity to buy for long-term investors, especially below $165.
Mentioned Stocks

Why Is Chewy Stock Falling, and is it a Buying Opportunity? | CHWY Stock Analysis
Parkev Tatevosian, CFA
Parkev argues that despite lowering its 2026 sales outlook, Chewy stock (CHWY) presents a great buying opportunity for long-term investors. He highlights the company's attractive valuation metrics and effective management, even amidst near-term consumer spending headwinds.
Mentioned Stocks

PetVivo CEO John Lai on the Long Term Investment Potential of veterinary biotech and medical devices
Chris Sain
Chris states that Pet Vivo Holdings is at a transformative turning point following its acquisition of PZO Bio's nano fiber technology. He argues that the company's ability to regenerate cartilage in animals and potentially humans positions it for massive growth in a multi-billion dollar market.
Mentioned Stocks

Revealed! 3 Undervalued Stocks I Just Bought
Parkev Tatevosian, CFA
Parkev states that he utilized recent market volatility to purchase shares in three undervalued companies: Netflix, Eli Lilly, and MasterCard. He believes these stocks offer significant upside potential relative to their fair values while providing crucial diversification away from his heavy concentration in artificial intelligence.
Mentioned Stocks

Nancy Pelosi Just Purchased THIS ‘10X Stock’
Felix Nikolas Prehn
Felix argues that Intel is a massive, generational opportunity because it is becoming a critical asset for U.S. national security with significant backing from both political parties. He states that while the company's current financials look poor, the strategic shift toward AI deployment and domestic manufacturing makes it a compelling play for the future.
Mentioned Stocks

Nvidia Stock Intrinsic Value - P/E Just 30!
Value Investing with Sven Carlin, Ph.D.
Sven states that while Nvidia's parabolic earnings growth has brought its P/E ratio down to roughly 32, the stock remains a high-risk gamble due to the cyclical nature of the semiconductor industry. He argues that the company's valuation is currently dependent on the sustainability of the AI investment boom, which may not last forever.
Mentioned Stocks

Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy? | LLY Stock Analysis
Parkev Tatevosian, CFA
Parkev states that Eli Lilly remains an excellent investment opportunity due to its continuous innovation in weight loss and oncology treatments. He argues that the company's strong profit margins and low correlation with the macroeconomy provide significant diversification benefits for investors, especially those heavily exposed to AI stocks.
Mentioned Stocks

Potential Explosive Move Coming‼️Meet Dr. Raza Bokhari, CEO of Medicus Pharma (MDCX)
Chris Sain
Chris states that Medicus Pharma is a promising biotech growth company focused on developing disruptive therapeutic assets for skin and prostate cancer. He highlights the firm's strategic business model of acquiring phase 2 clinical assets and positioning them for high-value exits through partnerships or acquisitions by major pharmaceutical players.
Mentioned Stocks

Early Buyers of this Stock will be forever GRATEFUL‼️
Jeremy Lefebvre Makes Money
Jeremy argues that the market is currently split, with memory chip and AI infrastructure stocks soaring while consumer and SaaS stocks struggle. He predicts a peak for memory chip stocks this year followed by a down cycle, and advises accumulating certain consumer and big tech names for long-term "ripper rallies" in the coming years.
Mentioned Stocks

The AI Boom Is Starting To Crack
Joseph Carlson After Hours
Joseph argues that the AI-driven capital expenditure cycle has reached a critical turning point as high component costs force major consumer tech companies to raise prices. Joseph states that while infrastructure providers like Micron are seeing record growth, the transition of these costs to the end consumer serves as a significant warning sign for the sustainability of the current tech boom.
Mentioned Stocks

Top Stocks I'm Buying For Huge Growth In July 2026
Ticker Symbol: YOU
Alex argues for a long-term investment strategy focused on AI and semiconductor stocks, presenting his top 10 picks. He highlights how these stocks collectively form a diversified portfolio designed to outperform the broader market by capitalizing on the AI revolution.
Mentioned Stocks

When to Buy MSFT Stock?
Daniel Pronk
Daniel argues that Microsoft's recent stock price decline has created a significant buying opportunity, as the company's valuation metrics are at decade lows while business fundamentals remain strong. He states that market concerns regarding AI disruption and high capital expenditure are overblown given Microsoft's massive distribution and accelerating cloud revenue.